GlassScriptPhysician profile
Philippe Nabbout
NPI 1811276801
$13,376.16
in general payments reported to CMS, 2019-2025
46 companies · $4,898 in 2025
The $4,898 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $204 · 2021: $639 · 2022: $815 · 2023: $891 · 2024: $4,918 · 2025: $4,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,646 · Food and Beverage: $2,937 · Honoraria: $2,040 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,645.50 |
| Food and Beverage | $2,936.63 |
| Honoraria | $2,040.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $2,983.37 | 2023-2025 | Adstiladrin |
| Urogen Pharma, INC. | $2,128.63 | 2024-2025 | |
| Telix Pharmaceuticals | $1,863.30 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $1,480.50 | 2025 | |
| Axonics, INC. | $649.11 | 2021-2024 | Bulkamid, Axonics |
| Boston Scientific Corporation | $439.75 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter |
| Astellas Pharma US INC | $429.09 | 2019-2022 | |
| Janssen Biotech, INC. | $301.25 | 2019-2025 | Erleada |
| Olympus America INC. | $287.89 | 2021-2025 | Itind System, Olympus, Bovie |
| Medtronic, INC. | $284.52 | 2021-2025 | Interstim |
| Novartis Pharmaceuticals Corporation | $271.44 | 2023-2025 | |
| Immunitybio, INC. | $243.15 | 2024-2025 | |
| Intuitive Surgical, INC. | $230.18 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $168.49 | 2019 | |
| Procept Biorobotics Corporation | $137.41 | 2022-2025 | Aquabeam System |
Show all 43 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Nabbout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.